But efficacy in NSCLC has slipped since the abstract, and a high rate of rash raises eyebrows.

But efficacy still needs to go up, as several groups try to combine PD-1 and CTLA-4 using differing approaches.

The Merck & Co drug's first successful phase 3 study might not be all it’s cracked up to be.

Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.

Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.

But toxicity will be closely watched in future trials.